Moderna made another deal with the US government

Moderna made another deal with the US government

The US government secured more COVID-19 vaccine doses

Moderna seems to have gained the trust of the American government, as they reached another agreement.

At the end of July, Moderna announced that it secured a funding of $472 million from the government to conduct an in-depth Phase III clinical trial for the COVID-19 vaccine they are producing.

Moderna announced that by the new agreement, it has to sell 100 million doses of its potential vaccine – mRNA-1273 – to the US government. The pharmaceutical company will be paid more than $1.5 billion for the doses. Under the deal, the US government has the option to buy 400 million more doses.

This move is part of the US government plan to provide the COVID-19 vaccine free of charge; however, medical staff may ask for money when administering it.

Following the news, Moderna stock price gained more than 8%. Year-to-date, the stock grew more than 250%, while USA500 went up 5.2%.

See what other pharmaceutical companies are getting help from the US government on CAPEX.com!

Sources: marketwatch.com


The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.